{"url_path":"/sec/crdf/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-254658-index.html","accession_number":"0001193125-26-254658","cik":"0001213037","ticker":"CRDF","issuer_name":"Cardiff Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-254658-index.html","primary_entity_key":"0001213037","primary_entity_name":"Cardiff Oncology, Inc."},"word_count":64,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\n99.1\n\n[Cardiff Oncology, Inc. Corporate Presentation](crdf-ex99_1.htm)\n\n \n\n2\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nCARDIFF ONCOLOGY, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 3, 2026\n\nBy:\n\n/s/ Mani Mohindru\n\n \n\n \n\n \n\nMani Mohindru\n\nInterim Chief Executive Officer\n\n \n\n3"}